Skip to main contentAI and Advanced
/
AMBALALSA · NSEMarket ticker unavailable · configure an authorised index feed
AM
NSE · Equity shares · Major Drugs-2.92 · -6.05%
Ambalal Sarabhai Enterprises AMBALALSA
NSE:INR 45.36
BSE:INR 31.32
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for AMBALALSA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 48.28
Day rangeINR 45.36 — INR 48
52-week rangeINR 30.15 — INR 49.98
Volume86,066
Market cap240.01
P/E13.77
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)202.27
Net Income (INR Cr)17.8
Rev Growth (5 Year %)4.33
EPS Growth (5 Year %)-9.52
P/E Ratio13.77
Book Value17.23
EPS2.42
Price/BV2.63Computed
Research path: Interpret Ambalal Sarabhai Enterprises's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AMBALALSAAmbalal Sarabhai Enterprises1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 281.13 | 270.04 | 249.52 |
| Accumulated Depreciation Total | -25.45 | -22.4 | -19.31 |
| Cash Equivalents | 2.25 | 2.1 | 5.13 |
| Other Liabilities Total | 0.82 | 0.65 | 0.68 |
| Accrued Expenses | 4.99 | 9.61 | 9.19 |
| Long Term Debt | 17.65 | 7.63 | 9.06 |
| Common Stock Total | 76.63 | 76.63 | 76.63 |
| Other Equity Total | -0.77 | -0.77 | -0.77 |
| Other Current Assets Total | 4.81 | 7.65 | 13.85 |
| Prepaid Expenses | 0.67 | 0.53 | 0.59 |
| Total Assets | 281.13 | 270.04 | 249.52 |
| Current Portof LT Debt/Capital Leases | 11.51 | 0.92 | 0.31 |
| Additional Paid-In Capital | 10.61 | 10.61 | 10.61 |
| Cash | 3.95 | 2.8 | 5.62 |
| Total Equity | 158.36 | 139.97 | 136.42 |
| Long Term Investments | 45.35 | 48.38 | 34.29 |
| Retained Earnings(Accumulated Deficit) | 71.88 | 53.5 | 49.95 |
| Total Common Shares Outstanding | 7.66 | 7.66 | 7.66 |
| Property/Plant/Equipment Total-Gross | 91.65 | 85.39 | 82.36 |
| Tangible Book Valueper Share Common Eq | 17.23 | 15.07 | 14.6 |
| Goodwill Net | 24.5 | 24.5 | 24.5 |
| Total Liabilities | 122.77 | 130.07 | 113.11 |
| Total Debt | 63.12 | 50.89 | 46.11 |
| Short Term Investments | 10.44 | 3.83 | 15.94 |
| Cashand Short Term Investments | 16.64 | 8.73 | 26.7 |
| Total Receivables Net | 80.68 | 71.55 | 55.59 |
| Notes Payable/Short Term Debt | 29.8 | 40.96 | 36.03 |
| Deferred Income Tax | 1.6 | 0 | 0.33 |
| Accounts Receivable-Trade Net | 48.32 | 44.8 | 27.53 |
| Property/Plant/Equipment Total-Net | 66.2 | 62.99 | 63.04 |
| Minority Interest | 0.01 | 0.01 | 0.01 |
| Total Current Liabilities | 98.54 | 120.4 | 102.32 |
| Total Inventory | 22.23 | 30.02 | 21.81 |
| Accounts Payable | 34.24 | 50.21 | 37.05 |
| Other Currentliabilities Total | 18.01 | 18.71 | 19.74 |
| Total Long Term Debt | 21.81 | 9.01 | 9.77 |
| Intangibles Net | 1.82 | 0.01 | 0.02 |
| Other Long Term Assets Total | 12.16 | 9.98 | 3.42 |
| Note Receivable-Long Term | 6.05 | 5.7 | 5.7 |
| Total Current Assets | 125.03 | 118.48 | 118.54 |
| Capital Lease Obligations | 4.16 | 1.38 | 0.71 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.87
Price to Sale Ratio1.19
Growth
Debt 5Yr CAGR %17.71
Margins
Operating Margin 12m3.46
Operating Margin 5y Avg4.49
Net Profit Margin 12m8.8
Net Profit Margin 5y9.27
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk55.71
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Aurobindo Pharma | INR 1,536.2 | 88,554.94 | 25.09 | — |
| Neuland Laboratories | INR 18,470 | 23,762.91 | 64.28 | — |
| Pfizer | INR 4,610.35 | 21,045.33 | 27.53 | — |
| Unichem Laboratories | INR 541.45 | 3,812.12 | 54.27 | — |
| Jagsonpal Pharmaceuticals | INR 222 | 1,456.38 | 34.27 | — |
Shareholding
Ownership
- Promoter
- 31.36%
- FII
- 0.34%
- Other
- 68.64%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Amara Raja Energy gets APPCB closure order revocation for manufacturing units - WhalesbookMarket news · 18 Jul 2026, 9:02 pm
Amara Raja Energy gets APPCB closure order revocation for manufacturing units Whalesbook
Amara Raja Energy FY26 Revenue Up 9% to ₹13,548 Cr; Declares ₹5.20 Dividend - WhalesbookMarket news · 17 Jul 2026, 3:36 pm
Amara Raja Energy FY26 Revenue Up 9% to ₹13,548 Cr; Declares ₹5.20 Dividend Whalesbook
360 ONE WAM Q1 FY27 Revenue Surges 29.9% to ₹1,273 crore; PAT Rises 16.1% - WhalesbookMarket news · 16 Jul 2026, 3:26 pm
360 ONE WAM Q1 FY27 Revenue Surges 29.9% to ₹1,273 crore; PAT Rises 16.1% Whalesbook
Amara Raja Commissions Lithium-Ion Cell Plant, Eyes EV Market - WhalesbookMarket news · 16 Jul 2026, 3:19 pm
Amara Raja Commissions Lithium-Ion Cell Plant, Eyes EV Market Whalesbook
Ambalal Sarabhai Enterprises Ltd is Rated Hold - MarketsMojoMarket news · 16 Jul 2026, 3:03 am
Ambalal Sarabhai Enterprises Ltd is Rated Hold MarketsMojo
Brought Forward Business Loss Eligible for Set-Off Against Short-Term Capital Gains Computed u/s 50: ITAT - TaxscanMarket news · 15 Jul 2026, 6:50 pm
Brought Forward Business Loss Eligible for Set-Off Against Short-Term Capital Gains Computed u/s 50: ITAT Taxscan
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsAudited Results & A.G.M.
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Ambalal Sarabhai Enterprises
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Ambalal Sarabhai Enterprises Limited is an India-based company that is engaged in the business of manufacturing pharmaceuticals and electronics. The Company's segments include Pharmaceuticals and Electronics. Asence Inc., a wholly owned subsidiary of the Company, specializes in the supply of pharmaceutical preparations (finished dosage forms and active pharmaceutical ingredients) to the international markets. Its subsidiary, Sarabhai Chemicals (India) Private Limited, offers products in the oncology, infertility and Uro-gynaec areas. Its wholly owned subsidiary, Suvik Hitek Pvt. Ltd., is engaged in manufacturing pharmaceutical products and marketing generics and veterinary products in the domestic market. Its subsidiary, Systronics (India) Limited, is a manufacturer of analytical and test and measuring instruments, distributing its products across India. Its other subsidiaries include Synbiotics Limited, Asence Pharma Private Limited, and Sarabhai M Chemicals Limited, among others.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- AMBALALSA
- BSE Code
- 500009
Questions
Stock FAQ
What is the symbol and ISIN of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has the symbol AMBALALSA and ISIN - INE432A01017.
What is the current price of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises is currently trading at INR 45.36.
What are the year high and year low of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a year high of INR 49.98 and a year low of INR 30.15.
What is the market capitalization of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a market capitalization of INR 240.01 crore.
What is the P/E ratio of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a P/E ratio of 13.77.
What is the dividend yield of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a dividend yield of 0.00%.
How is the financial performance of Ambalal Sarabhai Enterprises based on revenue, net income, and EPS?
Ambalal Sarabhai Enterprises has revenue of INR 202.27 crore, net income of INR 17.80 crore, and EPS of INR 2.41.
What is the book value of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a book value of INR 17.23.
What is the debt-to-equity ratio of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Ambalal Sarabhai Enterprises?
Ambalal Sarabhai Enterprises has a price-to-book ratio of 2.63 and a price-to-sales ratio of 1.19.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.